Low levels of a protein that helps to regulate B-cell activity may explain why these immune cells turn highly active, overproducing so many of the self-reactive antibodies that cause cold agglutinin disease (CAD), a study suggests. This protein, called complement receptor 1 (CR1), acts as a control on B-cells,…
Treatment with erythropoietin (EPO), a hormone that stimulates red blood cell production, safely increases hemoglobin levels in adults with cold agglutinin disease (CAD) and other autoimmune hemolytic anemias (AIHAs), according to a single-center study in Italy. Data show the treatment was effective in patients with abnormally low levels…
The use of Enjaymo (sutimlimab) was seen to prevent symptoms of cold agglutinin disease (CAD) from worsening in an elderly man in Japan following repeated vaccination against COVID-19, according to a case report. The patient had experienced CAD-related crises after receiving a third and fourth dose of the…
Twice-daily dosing of ANX1502, Annexon Biosciences’ experimental oral therapy for autoimmune conditions such as cold agglutinin disease (CAD), reached the desired levels in the blood of healthy volunteers who took part in a Phase 1 clinical trial. Taken by mouth as a liquid suspension, ANX1502 was well tolerated,…
Treatment with rituximab led to improvements in biomarkers of red blood cell destruction among people with cold agglutinin disease (CAD), but the improvements often were short-lived and reversible, according to a real-world analysis in the U.S. The therapy, which often is used off-label for the rare autoimmune disease, also…
A single infusion of one of two doses of SAR445088 — Sanofi’s potential successor to Enjaymo (sutimlimab-jome) — was well-tolerated by people with cold agglutinin disease (CAD) in a small Phase 1b clinical trial. The experimental therapy, also known as riliprubart, appeared to work as expected, with…
A free symposium on complement cascade-targeted treatment approaches for cold agglutinin disease (CAD) will be held live and virtually today ahead of the 2023 American Society of Hematology (ASH) meeting taking place in San Diego, California, Dec. 9-12. Announced in a tweet earlier this week, the session titled…
For a man in Japan, cold agglutinin disease (CAD) was complicated by pulmonary thrombosis, which occurs when a blood clot blocks a blood vessel in the lungs, and organizing pneumonia, a rare type of inflammation in the air sacs of the lungs. The man responded well to treatment with…
Among people with cold agglutinin disease (CAD), more than half were found to have a related autoimmune disorder called cryoglobulinemia, which affected symptom presentation but did not appear to affect survival. That’s according to a small study in which 59% of CAD patients tested positive for cryoglobulins, the…
BioCryst is working to develop a new oral therapy for cold agglutinin disease (CAD) that suppresses the immune complement cascade, and expects to have a lead candidate selected by 2025. This and other drug development plans were shared recently by the biotech company in a “R&D Day”…
Get regular updates to your inbox.